Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2014

01-12-2014 | SHORT REPORT

Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors

Authors: Mélodie Carbonnaux, Yann Molin, Pierre-Jean Souquet, Arnaud Tantin, Catherine Lombard-Bohas, Thomas Walter

Published in: Investigational New Drugs | Issue 6/2014

Login to get access

Summary

Background Everolimus, an mTOR inhibitor with immunosuppressive properties, is used in several types of advanced tumors. Materials and Methods We describe the first two cases of Pneumocystis jirovecii pneumonia in patients given everolimus for metastatic pancreatic neuroendocrine tumors. Results The first patient presented with respiratory symptoms in the context of grade 4 lymphopenia 2 weeks after starting everolimus; the diagnosis of Pneumocystis jirovecii pneumonia was made post-mortem. After suspecting everolimus-related interstitial pneumonitis in the second patient, Pneumocystis jirovecii was detected, and cotrimoxazole therapy led to a favorable outcome. Conclusion Everolimus may induce pneumonitis, lymphopenia and opportunistic infections. The time from treatment initiation to opportunistic infection may be short. Risk factors in oncology deserve further identification in order to start prophylaxis without delay.
Literature
1.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, and RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456CrossRefPubMed
2.
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529CrossRefPubMed
3.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, and RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523PubMedCentralCrossRefPubMed
4.
Saito Y, Nagayama M, Miura Y, Ogushi S, Suzuki Y, Noro R, Minegishi Y, Kimura G, Kondo Y, Gemma A (2013) A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. Jpn J Clin Oncol 43(5):559–562CrossRefPubMed
5.
Willemsen AECAB, De Vos FY, Jansen A, de Boer M, Tjan-Heijnen VCG, van Herpen CML (2014) Diagnostic challenges of respiratory adverse events during everolimus treatment. Target Oncol. doi:10.​1007/​s11523-014-0310-4 PubMed
6.
Loron M-C, Grange S, Guerrot D, Di Fiore F, Freguin C, Hanoy M, Le Roy F, Poussard G, Etienne I, Legallicier B, Pfister C, Godin M, Bertrand D (2014) Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. J Clin Oncol. doi:10.​1200/​JCO.​2013.​49.​9277 PubMed
7.
Albiges L, Chamming’s F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P (2012) Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 23(8):1943–1953CrossRefPubMed
8.
Azoulay E, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J (2009) Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 135(3):655–661CrossRefPubMed
9.
Caillet B, Souquet PJ, Velay B, Voloch A, Bernard JP (1992) Pneumocystis carinii pneumonia in a patient without any sign of immunodeficiency. Press Méd Paris Fr 1983 21(1):40–41
10.
Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M, Infectious Diseases Working Party (AGIHO), and German Society of Hematology and Oncology (DGHO) (2013) Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 92(4):433–442PubMedCentralCrossRefPubMed
11.
Masur H, Kaplan JE, Holmes KK, U.S. Public Health Service, and Infectious Diseases Society of America (2002) Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 137(5 Pt 2):435–478CrossRefPubMed
12.
Di Cocco P, Orlando G, Bonanni L, D’Angelo M, Clemente K, Greco S, Gravante G, Madeddu F, Scelzo C, Famulari A, Pisani F (2009) A systematic review of two different trimethoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence. Transplant Proc 41(4):1201–1203CrossRefPubMed
Metadata
Title
Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors
Authors
Mélodie Carbonnaux
Yann Molin
Pierre-Jean Souquet
Arnaud Tantin
Catherine Lombard-Bohas
Thomas Walter
Publication date
01-12-2014
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2014
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-014-0150-1

Other articles of this Issue 6/2014

Investigational New Drugs 6/2014 Go to the issue

PHASE II STUDIES

A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer

PRECLINICAL STUDIES

CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models

SHORT REPORT

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors

PHASE II STUDIES

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

PHASE I STUDIES

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

PHASE I STUDIES

Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits